The small molecule inhibitors or gene silencing of GLS1 expression has shown antitumor activity in a variety of cancers, including melanoma (Varghese et al., 2021), breast cancer (Gross et al., 2014), pancreatic cancer (Son et al., 2013), acute myeloid leukemia (Emadi et al., 2014), and malignant glioma (Yamashita et al., 2021)
This Medudy course is a video tutorial for physicians on the topic of "Semaglutide in chronic kidney disease and type 2 diabetes"
Selank Mechanism of Action in Research In experimental models, Selank influences multiple neurotransmitter systems
After that, if the results hold up, the drug would need to go through the FDA's rigorous review process